chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Site of injection - left deltoid - is sore to touch. No redness or erythema noted but some swelling noted, when compared to rt deltoid. Afebrile 97 degrees.
got covid after first dose; got covid after first dose; This is a spontaneous report from rugulatory authority, program Adverse Event Report, via a contactable consumer (patient). A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) at first dose, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient reported she/he got COVID after first dose on an unspecified date. The outcome of the events was unknown.  Information on the lot/batch number has been requested.
This case was reported by a physician via call center representative and described the occurrence of fever in a 81-year-old male patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX .5 ml. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced fever, injection site erythema and injection site pain. On an unknown date, the outcome of the fever, injection site erythema and injection site pain were recovered/resolved. It was unknown if the reporter considered the fever, injection site erythema and injection site pain to be related to SHINGRIX. Additional details were provided as follows: The reporting physician was the patient and reason for his phone call was unrelated to his experience with SHINGRIX. The age at vaccination was not reported but the patient could be 80 or 81 years old. The patient received dose of SHINGRIX in the right deltoid. The patient experienced a fever of 101.5 degree F, injection site redness of 2 to 3 inches in diameter and mild injection area pain. The fever resolved after 12 to 15 hours. The redness and pain had also resolved soon after. The patient had denied permission to contact their physician. Lab Comments: On an unknown date, lab test was performed.
Noticed I was still having pain at injection site and in same spot as injection given. As time went on my right shoulder became very painful. This has continued until now.
Mom presented to clinic state child has a rash.  Red rash noted on child back and stomach.  I instructed mom to take child to pediatric clinic or emergency room for evaluation.
Pt fainted in the waiting room on his way out of the building just a few minutes after receiving the Live, Intranasal Influenza Vaccine.
Vaginal bleeding  and joint pains. Joint pain went to urgent care on Friday 11/5/21.  No treatment. For vaginal bleeding went to doctor 11/12/21. Dr said it could have been vaccine or start of menopause.   Offered hormone treatment.  I refused hormones.  I do see some clotting in the blood at times.  I want to know if it actually was the vaccine and what to expect.
administration of KINRIX to a  2 YO; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 2-year-old female patient who received DTPa-IPV (Kinrix) (batch number E2154, expiry date 3rd March 2023) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 21st October 2021, the patient received Kinrix and Kinrix Pre-Filled Syringe Device. On 21st October 2021, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The 2 years old patient received dose of Kinrix, which led to inappropriate age at vaccine administration. The reporter consented to follow up.
H1N1 vaccine given 11/12/09. Pt states she developed hives on face, chin, lips, forehead 11/16, N/V for 12 hrs.
brachial neuritis;lt leg, lt arm & hand, rt arm & hand;pt recv vax 14JUN95;weakness, pain;
Patient's daughter called to complain that her mother was "sick" and couldn't get out of bed.
she got it and it is real red and hot where they gave it to her at referring to the location of the body; real sick; cant even get out bed; she got it and it is real red and hot where they gave it to her at referring to the location of the body; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (she got it and it is real red and hot where they gave it to her at referring to the location of the body), ILLNESS (real sick), MOBILITY DECREASED (cant even get out bed) and VACCINATION SITE ERYTHEMA (she got it and it is real red and hot where they gave it to her at referring to the location of the body) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH (she got it and it is real red and hot where they gave it to her at referring to the location of the body), ILLNESS (real sick), MOBILITY DECREASED (cant even get out bed) and VACCINATION SITE ERYTHEMA (she got it and it is real red and hot where they gave it to her at referring to the location of the body). At the time of the report, VACCINATION SITE WARMTH (she got it and it is real red and hot where they gave it to her at referring to the location of the body), ILLNESS (real sick), MOBILITY DECREASED (cant even get out bed) and VACCINATION SITE ERYTHEMA (she got it and it is real red and hot where they gave it to her at referring to the location of the body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.   This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in
Breakthrough infection; Rapid Antigen Test stayed positive from 12/18/2022 thru 12/26/2022. Symptoms: very mild fever (below 100), very mild cough, sore throat. Took Paxlovid from 12/20/2022 thru 12/24/2022. Paxlovid Rebound; Rapid Antigen Test stayed positive from 12/30/2022 thru 1/4/2023. Asymptomatic during Rebound.
Right eye will not blink closed; numbness on the right side of face, lip; and right side of mouth is turned down.
Diarrhea; Loss of appetite; Back pain; Vomitting; Pain in the arm at the injection site; Headache; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea), DECREASED APPETITE (Loss of appetite), BACK PAIN (Back pain), INJECTION SITE PAIN (Pain in the arm at the injection site) and HEADACHE (Headache) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Feb-2021, the patient experienced INJECTION SITE PAIN (Pain in the arm at the injection site) and HEADACHE (Headache). On 27-Feb-2021, the patient experienced DIARRHOEA (Diarrhea), DECREASED APPETITE (Loss of appetite), BACK PAIN (Back pain) and VOMITING (Vomitting). On 28-Feb-2021, VOMITING (Vomitting) had resolved. At the time of the report, DIARRHOEA (Diarrhea), DECREASED APPETITE (Loss of appetite), BACK PAIN (Back pain), INJECTION SITE PAIN (Pain in the arm at the injection site) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
BP: 151/100 Pulse 125 Resp:20 Temp 98.6 Weight 203 Height 5' 10.5" BMI: 28.751 02SAT 98% Tightness in chest and overall unwell feeling, presented myself to urgent care and was told to go to nearest hospital. Arrived at Hospital where multiple vials of blood were taken for tests, I was put on some sort of liquid iv and a few hrs later I was released. Since that time, I am always running hot, is the only way I can describe it. I can have the AC on in the house and it be 68 degrees and Im not cold but wife is freezing.
I had a fever that began about 16 hours after I received my first dose of the vaccine.  The fever escalated throughout the morning to 103.7 degrees before it began declining.  On 2/28 by 12:00 p.m. my temperature broke and was at my normal of 97.9.   No other issues were observed.    I tested positive for COVID-19 on 11/21/20.
Developed blister at injection site.  Blister broke and on 10/09 and 10/10/2012 developed more discomfort and swelling at the site.  1cm round eschar left deltoid area, induration and tenderness with no purulence.
Informatoin has been received from a physician referring to an unspecified number of patients of unknown age and gender. Pertinent medical history and drug reactions/allergies were not reported. Since 08-SEP-2015 the patients were vaccinated with doses of improperly stored VARIVAX (Merck) (lot # L010145, expiration date 24-MAR-2017, dose and route were not reported). Concomitant drug was not reported. No adverse effect was reported. This is one of the several reports from the same reporter. Additional information has been requested.
Patient began having blooding diarrhea the morning after vaccination. Has history of hemorrhoids with mild bleeding about 2 years prior. Patient reports that this was occurring with bowel movements only. was occurring about 6-7 times per day and then gradually decreased. Still having rectal bleeding with bowel movements, painless.
ENTIRE LEFT UPPER ARM WAS RED, HOT TO TOUCH, AND VERY SWOLLEN.  SOME ITCHING ALSO PRESENT.
Systemic: Allergic: Difficulty Breathing-Medium, Systemic: Chest Tightness / Heaviness / Pain-Medium, Systemic: Confusion-Mild, Systemic: Flushed / Sweating-Medium, Systemic: Tachycardia-Medium
PC from patient 12/15/11 with report of nausea, diarrhea & chills.
unable to stand for very long and it seems to be worse today than yesterday; diarrhea; feeling very weak; unable to stand for very long; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program. The reporter is the patient.  A 87 year-old female patient received bnt162b2 (COMIRNATY), administration date 28Sep2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CONDITION AGGRAVATED (non-serious) with onset 19Oct2021, outcome "not recovered", described as "unable to stand for very long and it seems to be worse today than yesterday"; DIARRHOEA (non-serious) with onset 18Oct2021, outcome "unknown", described as "diarrhea"; ASTHENIA (non-serious) with onset 18Oct2021, outcome "unknown", described as "feeling very weak"; DYSSTASIA (non-serious) with onset 18Oct2021, outcome "unknown", described as "unable to stand for very long".  Additional information: Patient started feeling very weak, having diarrhea, unable to stand for very long and it seems to be worse today than yesterday. She received her first dose of the Pfizer COVID-19 Vaccine (Comirnaty) on 28Sep2021 and is scheduled to receive her second dose today but will need to reschedule due to how she was feeling right now.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
pt states she got very nauseated immediately after taking the covid vax.  She has had joint pain, vomiting, fatigue, fever, and chills.  She got a burning sensation in her eyes and poor vision.  She had a tele-visit w/ her PCP about 7 days after getting vax.  She was told to take Tylenol 500 up to 8000mg for the pain, but the amount of meds has hurt her stomach.  She still had these symptoms and got the 2nd dose on 4/17/2021 in the right arm.  Her symptoms got worse.   She had to stop working due to the joint pain in her leg, arm, and shoulder.  She feels like something is swollen on the right side of her body in her ear and her throat.  She is having heart palpitations and breathing differently.   She has had blood work and still waiting on the results.  She had a negative Covid Test.  She is still in alot of pain and she feels like it has changed her whole life.  She is no longer a happy person as it has affected her mood.
3/27-right hip hurts, blotches, feverish/diaphoretic, mouth dry What happened as a result of the adverse event? (doctor visit, ED or urgent care visit, hospitalization, life threatening illness, disability/permanent damage, death, none of these): Took ibuprofen and diphenhydramine Advised patient to seek medical attention for worsening symptoms; go to urgent care or contact PCP first thing on Monday morning. 3/29-Spoke with caller, states that she is back to her "old self", rash resolved, no longer diaphoretic, Took benadryl, ibuprofen and B12. Advised to contact us if she needs anything.
Report received from a health professional on 14-SEP-2010. This case was initially reported to Merck (WAES number: 1009USA03334). A 40 year old female patient received H1N1 (brand and batch unspecified) on ??-???-2009. The patient's medical conditions include diabetes. On ??-???-2009, 4 days after administration of the suspect drug, the patient was sick. She was diagnosed with pneumonia. The event outcome was unknown. The original case report was for adverse events associated with AFLURIA. This case is documented in WAVES 2010026456. The company considered events serious due to medical significance. The company considered events possible in relation to the suspect drug. Information derived from this AE report does not change the current safety profile of the product.
Per patient's daughter the next day the patient's arm was purple and bruised.  She shared that it hurts to move her arm still, even after 2 weeks. Stated she has to use opposite arm to lift it up.  Advised that patient follow up with PCP.
faint during his workout; black marks on his finger knuckles; While he excersises, he stays out of air; This spontaneous case was reported by a consumer and describes the occurrence of SYNCOPE (faint during his workout) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In June 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SYNCOPE (faint during his workout) (seriousness criterion medically significant), IMMUNISATION REACTION (black marks on his finger knuckles) and DYSPNOEA EXERTIONAL (While he excersises, he stays out of air). At the time of the report, SYNCOPE (faint during his workout), IMMUNISATION REACTION (black marks on his finger knuckles) and DYSPNOEA EXERTIONAL (While he excersises, he stays out of air) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication information was reported. No treatment medication was reported.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company comment. This spontaneous case concerns a male patient of unknown age, with no medical history reported, who received the first dose of mRNA  1273 vaccine and experienced the serious medically significant unexpected event of syncope. Exact vaccination date and onset date of the event was not provided; hence latency and temporal association cannot be properly assessed. The report mentioned the patient presented exertional dyspnoea and faint during his workout. No further clinical information was available for medical reviewing. The benefit risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a male patient of unknown age, with no medical history reported, who received the first dose of mRNA  1273 vaccine and experienced the serious medically significant unexpected event of syncope. Exact vaccination date and onset date of the event was not provided; hence latency and temporal association cannot be properly assessed. The report mentioned the patient presented exertional dyspnoea and faint during his workout. No further clinical information was available for medical reviewing. The benefit risk relationship of mRNA-1273 is not affected by this report.
11 y/o received 2nd dose; This case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 11-year-old female patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   Previously administered products included Menveo (received 1st dose on 16th November 2021).   On 16th May 2022, the patient received the 2nd dose of Menveo. On 16th May 2022, unknown after receiving Menveo, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.   Additional Information: GSK Receipt Date: 18-MAY-2022 Reporter's Comments: Health care professional (HCP) reported that a patient who received primary vaccination of Menveo and received 2nd dose of Menveo. The reporter consented to follow-up. Additional Supportive Information: The 11 year old patient received 2nd dose of Menveo, which led to extra dose administered.
On Sunday I started having a stuffy nose, sore throat, and a cough so I took a COVID-19 test the next day which came back positive. I called the afterhours clinic connected to my Doctors office and they gave me Paxlovid for treatment. Since then I have had a slight fever and am very fatigued. I am still having these symptoms and have not recovered yet.
Varicella 9x10cm erythema, induration, hive. Prevnar 7x9cm erythema, induration.
This case was reported by a healthcare professional and described the occurrence of arm burning in an adult female subject who was vaccinated with ENGERIX B (GlaxoSmithKline).  There were no concurrent medications.  In July 2008 the subject received unspecified dose of ENGERIX B in the left arm.  At an unspecified time after vaccination with ENGERIX B, the subject experienced burning and stinging in the left arm.  At the time of reporting the outcome of the events was unspecified.
My son was extremely tired and slept most of the day following his shot, 6.5 hours versus 2.5 for naps. During his period of being awake he would stare off no where. He stopped engaging with people. He stopped smiling. He looked at his toys confused. He continues to tap his finger tips together. He doesn't respond to his father or I when we greet him. He is no longer soothed when we hold him. He doesn't cry much; he just seems empty. He stares at the ceiling or sometimes his mobile spinning around.
Positive Covid-19 Test; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (Positive Covid-19 Test) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SARS-COV-2 TEST POSITIVE (Positive Covid-19 Test). At the time of the report, SARS-COV-2 TEST POSITIVE (Positive Covid-19 Test) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Unknown.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
one patien was administered improperly stored VARIVAX; This spontaneous report was received from a medical assistance referring to a patient of unknown age and gender. The patient's pertinent medical history, concomitant therapies and drug reactions or allergies were not reported.  On unknown date in May 2020, the patient was vaccinated with improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) for prophylaxis (lot # S024369 has been verified to be a valid lot number, expiration date reported and validated as 16-AUG-2022 or lot # S032356 has been verified to be a valid lot number, expiration date reported and validated as 14-OCT-2021) (concentration, dose, frequency of vaccination scheme and route of administration, were not reported), that was reconstituted with properly stored sterile diluent (STERILE DILUENT) (lot #S016837 and expiration date 01-FEB-2022; los # S032591 and expiration date 16-AUG-2022; lot # T000495 and expiration date 03-JUN-2022). The reporter did not have the actual lot # used for either varicella virus vaccine live (Oka/Merck) (VARIVAX) or sterile diluent, so all lot # were included.  The vaccines underwent a temperature excursion in the range of -9 to -8 degrees Celsius (-7.18 degrees Celsius) for 30 hours as recorded by a data logger. There was a previous temperature excursion in the range of -14 to -10 degrees Celsius for 2 hours; -50 to -14.79 degrees Celsius for 1 hours.
Information has been received from a school nurse concerning a teacher with a history of chickenpox and shingles who was vaccinated with a dose of varicella virus vaccine live. On approximately 24-Sep-2003, the patient developed breakthrough varicella. Subsequently, the patient recovered. The school nurse also reported breakthrough varicella in children after therapy with varicella virus vaccine live, a case of breakthrough varicella in a second grade student (WAES #0311USA01766), and a case of breakthrough varicella in a child which resulted in hospitalization (WAES #0311USA00972). It was noted that the Centers for Disease Control and Prevention and state health department were involved in surveillance. Additional information has been requested.